178 related articles for article (PubMed ID: 18927309)
1. Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors.
de Bono JS; Kristeleit R; Tolcher A; Fong P; Pacey S; Karavasilis V; Mita M; Shaw H; Workman P; Kaye S; Rowinsky EK; Aherne W; Atadja P; Scott JW; Patnaik A
Clin Cancer Res; 2008 Oct; 14(20):6663-73. PubMed ID: 18927309
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
Kelly WK; Richon VM; O'Connor O; Curley T; MacGregor-Curtelli B; Tong W; Klang M; Schwartz L; Richardson S; Rosa E; Drobnjak M; Cordon-Cordo C; Chiao JH; Rifkind R; Marks PA; Scher H
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3578-88. PubMed ID: 14506144
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Giles F; Fischer T; Cortes J; Garcia-Manero G; Beck J; Ravandi F; Masson E; Rae P; Laird G; Sharma S; Kantarjian H; Dugan M; Albitar M; Bhalla K
Clin Cancer Res; 2006 Aug; 12(15):4628-35. PubMed ID: 16899611
[TBL] [Abstract][Full Text] [Related]
4. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.
Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Rasmussen A; Ooi CE; Buhl-Jensen P; Brown R; Evans TR; DeBono JS
Clin Cancer Res; 2008 Feb; 14(3):804-10. PubMed ID: 18245542
[TBL] [Abstract][Full Text] [Related]
6. Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes.
Drummond DC; Marx C; Guo Z; Scott G; Noble C; Wang D; Pallavicini M; Kirpotin DB; Benz CC
Clin Cancer Res; 2005 May; 11(9):3392-401. PubMed ID: 15867240
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
Kelly WK; O'Connor OA; Krug LM; Chiao JH; Heaney M; Curley T; MacGregore-Cortelli B; Tong W; Secrist JP; Schwartz L; Richardson S; Chu E; Olgac S; Marks PA; Scher H; Richon VM
J Clin Oncol; 2005 Jun; 23(17):3923-31. PubMed ID: 15897550
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study.
Münster P; Marchion D; Bicaku E; Schmitt M; Lee JH; DeConti R; Simon G; Fishman M; Minton S; Garrett C; Chiappori A; Lush R; Sullivan D; Daud A
J Clin Oncol; 2007 May; 25(15):1979-85. PubMed ID: 17513804
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.
Sandor V; Bakke S; Robey RW; Kang MH; Blagosklonny MV; Bender J; Brooks R; Piekarz RL; Tucker E; Figg WD; Chan KK; Goldspiel B; Fojo AT; Balcerzak SP; Bates SE
Clin Cancer Res; 2002 Mar; 8(3):718-28. PubMed ID: 11895901
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Ryan QC; Headlee D; Acharya M; Sparreboom A; Trepel JB; Ye J; Figg WD; Hwang K; Chung EJ; Murgo A; Melillo G; Elsayed Y; Monga M; Kalnitskiy M; Zwiebel J; Sausville EA
J Clin Oncol; 2005 Jun; 23(17):3912-22. PubMed ID: 15851766
[TBL] [Abstract][Full Text] [Related]
11. Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors.
Saif MW; Erlichman C; Dragovich T; Mendelson D; Toft D; Burrows F; Storgard C; Von Hoff D
Cancer Chemother Pharmacol; 2013 May; 71(5):1345-55. PubMed ID: 23564374
[TBL] [Abstract][Full Text] [Related]
12. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo.
Graham C; Tucker C; Creech J; Favours E; Billups CA; Liu T; Fouladi M; Freeman BB; Stewart CF; Houghton PJ
Clin Cancer Res; 2006 Jan; 12(1):223-34. PubMed ID: 16397046
[TBL] [Abstract][Full Text] [Related]
14. Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors.
Shimizu T; LoRusso PM; Papadopoulos KP; Patnaik A; Beeram M; Smith LS; Rasco DW; Mays TA; Chambers G; Ma A; Wang J; Laliberte R; Voi M; Tolcher AW
Clin Cancer Res; 2014 Oct; 20(19):5032-40. PubMed ID: 25107918
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.
Fujiwara Y; Yamamoto N; Yamada Y; Yamada K; Otsuki T; Kanazu S; Iwasa T; Hardwick JS; Tamura T
Cancer Sci; 2009 Sep; 100(9):1728-34. PubMed ID: 19575752
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report.
; Fouladi M; Furman WL; Chin T; Freeman BB; Dudkin L; Stewart CF; Krailo MD; Speights R; Ingle AM; Houghton PJ; Wright J; Adamson PC; Blaney SM
J Clin Oncol; 2006 Aug; 24(22):3678-85. PubMed ID: 16877737
[TBL] [Abstract][Full Text] [Related]
18. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.
Chen L; Meng S; Wang H; Bali P; Bai W; Li B; Atadja P; Bhalla KN; Wu J
Mol Cancer Ther; 2005 Sep; 4(9):1311-9. PubMed ID: 16170022
[TBL] [Abstract][Full Text] [Related]
19. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Bali P; Pranpat M; Bradner J; Balasis M; Fiskus W; Guo F; Rocha K; Kumaraswamy S; Boyapalle S; Atadja P; Seto E; Bhalla K
J Biol Chem; 2005 Jul; 280(29):26729-34. PubMed ID: 15937340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
